StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Research analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report released on Saturday. The firm set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

BCLI opened at $1.73 on Friday. The business has a 50 day simple moving average of $2.02 and a two-hundred day simple moving average of $2.56. The firm has a market capitalization of $9.86 million, a price-to-earnings ratio of -0.36 and a beta of 0.26. Brainstorm Cell Therapeutics has a one year low of $1.05 and a one year high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.